Humasis Co. Ltd. (KOSDAQ:205470)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,005.00
-70.00 (-1.72%)
Apr 15, 2026, 8:37 AM KST
-41.23%
Market Cap 90.64B
Revenue (ttm) 30.11B
Net Income (ttm) -15.62B
Shares Out 22.63M
EPS (ttm) -690.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 361,834
Average Volume 279,682
Open 4,075.00
Previous Close 4,075.00
Day's Range 3,990.00 - 4,295.00
52-Week Range 3,315.00 - 9,725.00
Beta 0.11
RSI 53.22
Earnings Date May 15, 2026

About Humasis

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the quali... [Read more]

Industry Medical - Equipment & Services
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 205470
Full Company Profile

Financial Performance

In 2025, Humasis's revenue was 30.11 billion, an increase of 18.49% compared to the previous year's 25.41 billion. Losses were -15.62 billion, -48.69% less than in 2024.

Financial Statements

News

There is no news available yet.